Evidence map›Paper›PMID 17074791›Full record

ArticleAntimicrobial agents and chemotherapy2007

Inhibition of anthrax protective antigen outside and inside the cell.

Marina V Backer, Vimal Patel, Brian T Jehning, Kevin P Claffey, Vladimir A Karginov, Joseph M Backer

Open access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Designing inhibitors of anthrax toxin.Expert opinion on drug discovery · 2014
    Review
  5. Cyclodextrin derivatives as anti-infectives.Current opinion in pharmacology · 2013
    Review
  6. Review
  7. Anthrax toxin protective antigen--insights into molecular switching from prepore to pore.Protein science : a publication of the Protein Society · 2012
    Review
  8. Imaging tumor endothelial marker 8 using an 18F-labeled peptide.European journal of nuclear medicine and molecular imaging · 2011
    Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Marina V BackerSibTech, Inc., 705 North Mountain Road, Newington, CT 06111, USA.
Vimal Patel
Brian T Jehning
Kevin P Claffey
Vladimir A Karginov
Joseph M Backer
UConn Health · US

Funding

Targeted delivery of anti-anthrax therapeuticsR43AI054060 · NIAID · SIBTECH, INC. · PI BACKER, JOSEPH M · 2003 to 2003
$107k
NIAID NIH HHS 1 R43AI054060-01
6 · The paper itself

Abstract

In the course of Bacillus anthracis infection, B. anthracis lethal factor (LF) and edema factor bind to a protective antigen (PA) associated with cellular receptors ANTXR1 (TEM8) or ANTXR2 (CMG2), followed by internalization of the complex via receptor-mediated endocytosis. A new group of potential antianthrax drugs, beta-cyclodextrins, has recently been described. A member of this group, per-6-(3-aminopropylthio)-beta-cyclodextrin (AmPrbetaCD), was shown to inhibit the toxicity of LF in vitro and in vivo. In order to determine which steps in lethal factor trafficking are inhibited by AmPrbetaCD, we developed two targeted fluorescent tracers based on LFn, a catalytically inactive fragment of LF: (i) LFn site specifically labeled with the fluorescent dye AlexaFluor-594 (LFn-Al), and (ii) LFn-decorated liposomes loaded with the fluorescent dye 8-hydroxypyrene-1,3,6-trisulfonic acid (LFn-Lip). Both tracers retained high affinity to PA/ANTXR complexes and were readily internalized via receptor-mediated endocytosis. Using fluorescent microscopy, we found that AmPrbetaCD inhibits receptor-mediated cell uptake but not the binding of LFn-Al to PA/ANTXR complexes, suggesting that AmPrbetaCD works outside the cell. Moreover, AmPrbetaCD and LFn-Al synergistically protect RAW 264.7 cells from PA-mediated LF toxicity, confirming that AmPrbetaCD did not affect the binding of LFn-Al to receptor-associated PA. In contrast, AmPrbetaCD did not inhibit PA-mediated internalization of LFn-Lip, suggesting that multiplexing of LFn on the liposomal surface overcomes the inhibiting effects of AmPrbetaCD. Notably, internalized LFn-Al and LFn-Lip protected cells that overexpressed anthrax receptor TEM8 from PA-induced, LF-independent toxicity, suggesting an independent mechanism for PA inhibition inside the cell. These data suggest the potential for the use of beta-cyclodextrins in combination with LFn-Lip loaded with antianthrax drugs against intracellular targets.

Indexed as

AnimalsAntigens, BacterialBacillus anthracisBacterial Toxinsbeta-CyclodextrinsCell LineCHO CellsCricetinaeCricetulusDose-Response Relationship, DrugEndocytosisLuminescent ProteinsMicroscopy, FluorescenceMonocytesPeptide FragmentsProtein Bindinganthrax toxinAntigens, BacterialBacterial Toxinsbeta-CyclodextrinsLuminescent ProteinsPeptide Fragmentsper-6-(3-aminopropylthio)-beta-cyclodextrin

Identifiers

PMID17074791
PMCPMC1797656
OpenAlexW2073522496

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.